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Summary 
Cytotoxic T  lymphocyte (CTL) activation requires specific T  cell receptor (TCR)-class  I ma- 
jor histocompatibility complex (MHC)  antigen  complex interactions  as well as the participa- 
tion of coreceptor or accessory molecules on the surface of CTL. CD8 can serve as a corecep- 
tot in that it binds to the same MHC  class I molecules as the TCR  to facilitate efficient TCR 
signaling. In addition, CD8 can be "activated" by TCR stimulation to bind to class I molecules 
with high avidity, including class I not recognized by the TCP, as antigenic complexes  (non- 
antigen [Ag] class I), to augment CTL responses and thus serve an accessory molecule function. 
A  Glu/Asp227--+Lys substitution  in the class  I cx3 domain acidic loop abrogates lysis of target 
cells expressing these mutant molecules by alloreactive CD8-dependent CTL. Lack of response 
is attributed to the destruction of the CD8 binding site in the 0~3 domain which is likely to dis- 
rupt CD8  coreceptor function.  The relative importance  of the  class  I e~3 domain acidic loop 
Glu227 in coreceptor as opposed to accessory functions of CD8 is unclear.  To address this is- 
sue, we examined CTL adhesion and degranulation in response to immobilized class I-pep- 
tide complexes formed in vitro from antigenic peptides and purified class I molecules contain- 
ing wild-type  or G1u227--+Lys substituted  oL3 domains.  The  0¢3  domain mutant  class I-peptide 
complexes were bound by CTL and triggered degranulation,  however to much lower levels 
than wild-type class I-peptide complexes.  In further experiments,  it is directly demonstrated that 
the 0~3 domain mutant class I molecules, which lack the Glu227 CD8 binding site, still serve as 
TC1L-activated, avidity-enhanced CD8 accessory ligands. However, mutant class I-peptide Ag 
complexes failed to effectively serve as CD8 coreceptor ligands to initiate TCR-dependent sig- 
nals required to induce avidity-enhanced CD8 binding to coimmobilized non-Ag class I mol- 
ecules. Thus the Glu227--+Lys mutation effectively distinguishes  CD8 coreceptor and avidity- 
enhanced CD8 accessory functions. 
C 
Ytotoxic T  lymphocyte activation is a process that in- 
volves multiple  cell surface  protein  interactions  with 
antigen-bearing target cells and a cascade of signal transduc- 
tion  events  which lead  to proliferation  and  effector func- 
tions  (1,  2).  T  cell receptor interaction  with MHC  class  I 
molecules bound with antigenic peptides  on target cells is 
responsible  for the  specificity of CD8 +  CTL  recognition. 
So-called coreceptors and accessory molecules  on the sur- 
face of CTL interact with their respective ligands on target 
cells  and also contribute  to T  cell activation by increasing 
the avidity between CTL and targets, amplifying TCR-ini- 
tiated signals, transducing distinct signals,  or a combination 
of these mechanisms (1,  2). 
The CD8  molecule is typically expressed  as a disulfide- 
linked ot/[3 heterodimer on the mature murine CD8 + T  cell 
subset and plays a critical role in CD8-dependent CTL rec- 
ognition and activation (3).  In CTL recognition,  CD8 can 
function as a coreceptor by binding to the same MHC class I 
molecules as the TCR  (3-5), as well as an accessory mole- 
cule  by binding  to  any class  I  molecules,  including those 
which do not interact with the TCIL (non-Ag class I) (6-10). 
The  relative  importance  of CD8  coreceptor  or  accessory 
interactions  with  class  I  molecules  toward  T  cell  activation 
may depend on the density of specific MHC  class I-peptide 
complexes  on the  target  cells  as well  as the  affÉnity  of the 
interaction between the MHC-peptide  complexes and the 
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generated which activate CD8 to a state of higher avidity, 
and consequently, the  "activated," avidity-enhanced CD8 
binds MHC class I molecules and facilitates CTL activation 
either by strengthening the interactions between CTL re- 
ceptors and their ligands, or transducing additional signals 
for T  cell activation (6-10). 
It has been shown by site-directed mutagenesis that the 
negatively charged loop  (residues 222-229)  in the  highly 
conserved e~3  domain of MHC  class  I  molecules plays an 
important role  in  CD8-dependent CTL  recognition and 
activation (4,  13-15). For instance, the  Glu227--+Lys sub- 
stitution in the D d c¢3  domain abrogates the  CD8-depen- 
dent,  alloreactive  CTL  killing  of target  cells  expressing 
these mutant molecules (4,  13, 14).  The inability ofmurine 
CD8-dependent CTL to lyse targets bearing the e¢3 mutated 
class I  molecules was  attributed to  the  disruption of CD8 
interaction with class  I  (13-15).  Consistent with these re- 
sults, mutational analysis and adhesion assays using CD8ot- 
transfected Chinese hamster ovary cells,  demonstrate that 
the acidic loop in (x3 domain of HLA class I molecules is a 
binding site  for  human CD8o~/ot  homodimers  (15).  The 
site(s)  on  the  MHC  class  I  molecules that  participate  in 
high  avidity  TCR-activated  CD8  binding has  not  been 
identified. Whether the (x3 domain acidic loop is essential 
for TCR-activated CD8ot/[3 heterodimer binding to class I 
is unknown. That mutations in the c~2 domain of HLA class 
I  molecules can also interfere with CD8odot binding sug- 
gest the possibility that other sites in addition to the c~3 do- 
main on class I may be involved in CD8 interaction(s) (16, 
17), perhaps including activated CD8 binding. 
Using immobilized purified chimeric  class  I  molecules 
consisting of Db0~10L2 or  Kbodot2  and Ddo~3 domains, in 
which the DdoL3 domain is either the wild-type or the mu- 
tant with a Glu227--~Lys substitution, the role of Glu227 in 
the or3 domain acidic loop of class I in CD8 coreceptor and 
TCR-triggered avidity-enhanced CD8 accessory functions 
of cloned CTL was assessed.  The mutant class ! effectively 
serves as an activated CD8 accessory ligand, indicating that 
Glu227 is not required for this type of CD8 interaction. In 
contrast, the purified mutant class I molecules were unable 
to  effectively coengage TCR  and CD8  to  initiate TCR- 
dependent activation events. 
Materials  and Methods 
mAbs.  A murine hybridoma that secretes an IgG2  a mAb rec- 
ognizing H-2 D b molecules, B22.249  (18), was a gift from Dr. U. 
Hammerling (Memorial  Sloan-Kettering Cancer  Center,  New 
York).  The Kb-specific mAb, Y3  (IgG2b) (19), and Dd-specific 
mAbs, 34-5-8s (IgG2a) (20) and 34-2-12s (IgG2~) (20) were pro- 
duced from their respective hybridomas obtained from American 
Type Culture Collection (ATCC; Rockville, MD). The rat anti- 
mouse  CD8-producing hybridoma, 2.43  (IgG2b) (21) was  ob- 
tained from ATCC, and the YTS169.4 mAb (rat IgG2b) (22) was 
purchased from Cedarlane Laboratories  (Hornby, Ontario, Can- 
ada).  The  hamster anti-mouse TC1Kc(/[3 mAb,  H57-597  (23), 
was purchased  from Pharmingen (San Diego, CA). 
Transfectant Cell Lines Expressing  Chimeric H-2 Class I with Wild- 
Type or Mutant oe3 Domains.  M12  (H-2a),  a  B  lymphoma cell 
line, was transfected with chimeric class I genes as described  (13, 
24, 25). Exon shuffled genes consisting of the oL1 and or2 domain of 
the H-2 D b or K  b genes and either the wild-type or Glu227---->Lys 
substituted o~3 domain of the H-2 D a (13) were transfected  into 
the M12 cell line by electroporation, and are referred to herein as 
M12.Db/Dawt,  M12.Db/DaLys,  M12.KB/Dawt,  and  M12.Kb/ 
DaLys, respectively. 
Cloned  CTLs.  Clone 3/4 is specific for H-2 D b and the influ- 
enza nucleoprotein (NP) 1 (365-380)  of A/PlK/8/34 influenza vi- 
rus and was maintained as described previously (7). The NP pep- 
tide used in this study is a 10-mer (NP366-374) with a tyrosine at 
the NH  2 terminus (Y-ASNENMETM) that was synthesized and 
purified at Multiple Peptide Systems (San Diego, CA). The Kb-allo  - 
specific CTL clone, 11, was described previously (26, 27). 
Purification  of Chimeric  Murine  MHC  Class  I  Molecules  Bearing 
Wild-Type or Mutant ex3 Domains.  The chimeric H-2 class I mole- 
cules, Db/Ddwt,  Db/DdLys, Kb/Dawt, and Kb/DdLys were puri- 
fied  from  0.5-1.0  X  10 l°  transfectant  cells by immunoafflnity 
chromatography as described (27, 28) with modifications. B22.249 
(D  b o.1; 29) and Y3 (K  b el2; 30) mAb columns were used for im- 
munoaffinity purification of DB/D a and KB/D  a chimeric mole- 
cules,  respectively.  To avoid cross contamination, separate  col- 
umns  were  used  for  the  wild-type  and  the  mutant  class  I 
molecules.  Detergent lysates of the transfectant  cells were passed 
over the B22.249  or Y3  columns. Columns were washed  with 
0.1% deoxy cholate  (DOC), 40 mM NaC1, 10 mNl Tris, pH 8.2, 
and 0.5% DOC, 0.65  M  NaC1, 10 mM Tris,  pH 8.5.  The chi- 
meric molecules  were  then eluted  from  the columns using 0.5% 
DOC, 0.15 M NaC1, 15 mM Na2CO  3, pH 10.5 (27). Solid-phase 
ELISA of purified class I chimeric molecules was performed with 
various  mAbs as described  previously (28). Peak  fractions show- 
ing strong ELISA reactivities were pooled and used as described 
(27, 28). Protein quantitation was determined by Micro-BCA as- 
say (Pierce Chemical Co., Rockford, IL). Other immunoaffin- 
ity-purified H-2 class I used in this study,  including K  b and D b 
isolated from EL4 cells and K  k isolated from 1KDM-4, as well as I-E  a 
class  II  molecules isolated  from A20.Cy,  were  purified as  de- 
scribed previously (28, 31). 
Assays for CTL Binding and Degranulation.  CTL  degranulation 
was assessed by measuring the serine esterase (SE) activity released 
into the medium with the N'-benzyloxycarbonyl-L-lysine  thioben- 
zyl ester (BLT) assay as described (32). Stimulator cells were pulsed 
with the NP peptide for 30 min at 1KT, washed three times with 
2% FCS-RPMI, and 3 X 105 stimulator cells were incubated with 
105 cloned CTL for 4 h. 20 ~1 ofsupematant was recovered and the 
BLT reactions proceeded for 20 min, whereupon the ODa0sn  m was 
determined.  SE  release  is  calculated  as  AOD405 .....  =  OD40s  .... 
(CTL +  stimulators)  -  OD40snm(CTL  alone). 
CTL adhesion and degranulation responses to purified class I 
and coimmobilized proteins have  been described  previously in 
1Abbreviations  used in  this paper: NP,  influenza nucleoprotein; pD  b,  D b 
molecules purified from EL4  cells; pDb/D  d Lys, purified chimeric D  b 
(etlc¢2) and D  d ((x3 with  Glu227-+Lys substitution) molecules; pDb/ 
Ddwt, purified chimeric D  b ((xl(x2) and D  a (~3 wild type) molecules; 
pKb/DdLys, purified chimeric K  b ((xl~x2) and D  d (~3 with Glu227-+Lys 
substitution) molecules;  pKb/Ddwt, purified chimeric K  b ((xloL2) and D  o 
(~3 wild type) molecules;  pK  b, K  b molecules  purified from EL4 cells; SE, 
serine esterase. 
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rified class I molecules, the class I-bearing wells were incubated 
with NP peptide resuspended in 2% FCS-PBS at 37°C for 16 h to 
form peptide-antigen complexes as previously described (7, 32). 
Either 1 or 2  ×  105 51Cr-labeled CTL were incubated for 4 h at 
37°C  on  protein-bearing plate  wells,  and  unbound  cells  were 
then removed. In experiments using fluid phase anti-TCR-o~/[3 
mAb, the antibody was added to CTL in suspension and the cells 
immediately placed into  class I-bearing wells.  Cell binding was 
calculated as: percent specific cell bound =  100  ×  [(cpm bound)/ 
(total cpm-spontaneous cpm)]. Degranulation by CTL was deter- 
mined simultaneously with CTL binding from the same wells. SE 
release is  expressed as  AOD405  ....  =  OD40snm(CTL  +  immobi- 
lized class I)  -  OD40snm(CTL  +  wells blocked with 2%  FCS in 
PBS). All determinations were done in triplicate for each condi- 
tion unless specified. 
CytotoxicityAssay.  Target  cells  were  labeled with  SlCr and 
then pulsed with NP peptide at the concentrations indicated. Af- 
ter  washing,  104  target  cells  were  incubated  with  the  CD8- 
dependent, NP-specific CTL clone 3/4 at a 5:1 E/T ratio for 5 h 
in V-bottom microtiter plates in triplicate. Percent specific SlCr 
release was  calculated as:  [(experimental release  -  spontaneous 
release)/(maximum release -  spontaneous release)]  ×  100.  Re- 
sults are expressed as mean percent specific SlCr release.  In all ex- 
periments, the spontaneous 51Cr release was <7.5% of the total. 
Anti-CD8 mAb-Blocking Experiments.  For anti-CD8 mAb-block- 
ing experiments, the cloned CTL were incubated with the indi- 
cated CD8-specific antibodies at room temperature for 30  rain 
before carrying out the assays. Anti-CD8 mAb, 2.43 was used at 
dilution  1:4  of the  culture  supematant  and  purified YTS169.4 
was used at 5 Ixg/ml. 
Results 
Antigen-specific, CD8-dependent  CTL Recognition and Lysis 
of Target Cells Bearing MHC Class I with  Wild-Type or Mu- 
tant oe3 Domains.  It has been shown that CDS-dependent 
CTL either failed or had greatly reduced ability, to lyse tar- 
get cells with amino acid substitutions in residues 222-229 
of the eL3 domain of MHC  class I molecules (4,  13-15, 24, 
33).  The  inabihty  or  reduced  ability of CDS-dependent 
CTL to lyse these targets was attributed to failure of CD8 
to bind the mutated MHC  class I  molecules on  the target 
cells.  In the  present study, we  examined the  ability of an 
H-2 Db-restricted, influenza NP~pecific CTL,  clone 3/4, 
to lyse, or degranulate in response to, target cells transfected 
with a chimeric cDNA encoding the D b odlx2 domain and 
D a o~3 domain.  The D a o~3 domain is either the wild-type 
or  mutant  with  a  Glu227--)Lys  substitution  (13,  24,  25). 
Both  the  transfectants,  M12.Db/Dawt  or M12.Db/D%ys, 
express comparable levels of the hybrid D b molecules as de- 
tected by FACS  ® analysis using a Db-specific mAb, B22.249 
(data  not  shown).  The  target  cells were  pulsed  with  NP 
peptide at different concentrations, and cytolysis was mea- 
sured by 51Cr release. As expected, and similar to our pre- 
vious report (24), M12.Db/Dawt target cells were killed by 
clone 3/4 to a level comparable to EL4  (H-2b), which ex- 
presses natural D b molecules (Fig. 1 A). Clone 3/4 also lysed 
M12.Db/D%ys,  with two significant differences compared 
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Figure  1.  Antigen-specific,  CD8 +  CTL  clone  lysis  of  target  ceils 
bearing MHC  class I  molecules with wild-type or mutant a3  domains. 
(A)  Lysis  of Ml2.Db/Dawt,  M12.Db/D%ys  transfectant  cells and  EL4 
cells by an influenza NP-specific CTL, clone 3/4. 51Cr-labeled targets were 
pulsed with  the  influenza NP  peptide  (Y-NP366-374)  at  the  indicated 
concentrations.  104 targets were incubated together with clone 3/4 effec- 
tor cells at a 5:1 E/T ratio at 37°C for 5 h. Effects of CD8-specific mAbs on 
clone 3/4 CTL killing of Ml2.Db/DJwt  (B)  and M12.Db/D%ys  (C) cells 
were determined. Clone 3/4 effector ceils were incubated with anti-CD8 
mAbs  at  RT  for  30  rain  before  assay with 51Cr-labeled,  NP  peptide- 
pulsed targets. 2.43  mAb was used as  1:4 dilution of culture supematant 
and purified YTS169.4  used at the concentration of 5  ~g/ml. No lysis of 
targets was seen without NP  peptide pulsing (data not shown).  Percent 
specific lysis is expressed as the  mean  of triplicate wells and variation is 
<8% of the mean. 
to M12.Db/Dawt lysis (Fig. 1 A). First, the maximal levels 
of lysis of M12.Db/D%ys  (20%)  were  only  one-third  to 
one-half of that of M12.Db/Ddwt  (40-50%).  Second, the 
concentration of peptide required to obtain significant lysis 
was >100-fold higher in M12.Db/D%ys  than in M12.DU/ 
Dawt. These results are consistent with our previous report 
in which lysis by a Kb-restricted, OVA-specific CTL clone 
of M12  cells transfected with Kb/D%ys gene was substan- 
tially lower  and  required  higher  concentrations  of OVA 
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Figure 2.  Antigen-specific CTL clone degranulation responses to cells 
bearing wild-type or ~3 domain-mutated class I molecules. (A) Degranu- 
lation  of an  influenza NP-specific  CTL  clone,  3/4,  in  response to 
M12.Db/Dawt and M12.Db/DdLys transfectants. Both transfectants were 
pulsed with NP peptide at the indicated concentrations. After washing, 
3 X 105 transfectant cells  were incubated with l0  s clone 3/4 cells at 37°C 
for 4 h. Effects ofanti-CD8 antibodies on clone 3/4 degranulation in re- 
sponse to M12.Db/Ddwt (B) and M12.Db/DdLys (C') cells were also de- 
termined. Clone 3/4 cells were incubated with anti-CD8  antibodies at 
room temperature for 30 n'fin before incubating with the peptide-pulsed 
transfectant cells. Anti-CD8 mAb, 2.43, was used at 1:4 dilution of cul- 
ture supernatant, and YTS169.4 used at the concentration of 5 p~g/ml. In 
all the panels, SE release is expressed as the mean of triplicate wells and 
variation is < 10% of the mean. 
peptide  than  target  cells  transfected  with  the  KU/Ddwt 
gene  (24).  M12.Db/Ddwt  cell lysis by clone 3/4  CTL was 
almost  completely blocked by  CD8oL-specific mAbs  2.43 
and YTS169.4  at lower peptide concentrations, while par- 
tially  inhibited  when  peptide  concentrations  were  high 
(Fig. 1 B). This confirmed that the clone 3/4 killing is CD8 
dependent,  and  also showed  that  CD8  dependency is re- 
lated to  the  numbers  of MHC  class  I-peptide complexes 
involved in the CTL-target interactions (11,  12).  Interest- 
ingly,  even  the  cytolysis of M12.Db/DdLys  was  partially 
blockable by  anti-CD8  mAbs  (Fig.  1  C)  suggesting  that 
CD8  may still participate to some extent in CTL recogni- 
tion of mutant class I-peptide complexes. Similar to the cy- 
Table 1.  ELISA Reactivity of  plY'/Dawt and pD~/DaLys 
mAbs*  Specificity  pDb/Ddwt  pDb/DaLys 
B22.249  D b al  1.062  +_ 0.052*  1.092  _+ 0.048 
34-5-8s  D d ~1c~2  0.003  _+ 0.001  0.013  -  0.002 
34-2-12s  D d or3  0.347  4- 0.032  0.009  _+ 0.002 
Y3  ;  K b oL2  0.005  +  0.001  0.017 +_ 0.001 
ELISA reactivity ofpDb/Dawt and pDb/DdLys determined with various 
mAbs. 
*First antibody used in solid-phase ELISA assay: purified B22.249 and 
Y3 were diluted into 2% FCS-PBS and used at 2.5 btg/ml; 34-5-8s and 
34-2-12s were used as culture supematants in 10% FCS-RPMI at 1:4 
dilution. 
*Results were expressed as mean OD490n  m ~  SD of triplicate wells. 
tolysis results, M12.Db/Dawt  cells triggered a  substantially 
stronger SE release than M12.Db/D%ys cells, and these re- 
sponses were peptide dose dependent (Fig. 2 A). Clone 3/4 
degranulation  responses  triggered by both  M12.Db/Dawt 
and M12.Db/DaLys cells were CD8 dependent, as the anti- 
CD8  mAbs  effectively  inhibited  the  degranulation  re- 
sponses (Fig. 2, B and C). 
Direct Comparison of CTL Adhesion and Response to Purified 
Da/Dawt and Da/DaLys Pulsed with NP Peptide Ag.  FACS  ® 
analysis  showed  that  both  M12.Db/Ddwt  and  M12.Db/ 
DaLys transfectant  cells expressed other  class  I  molecules, 
e.g., D d (data not shown),  and may express other cell sur- 
face accessory molecule ligands. To  directly compare Db/ 
Ddwt  -  and Db/DdLys-peptide complexes in CTL recogni- 
tion  and  activation,  we  purified Db/Ddwt  and Db/D%ys 
molecules  for  use  in  solid-phase CTL  recognition  assays 
(7,  27,  32).  Since B22.249  mAb recognizes an or1  domain 
epitope of D b, independent of the o~3 domain  (29),  it was 
used for immunoaffinity purifications of Db/Ddwt and Db/ 
D%ys  chimeric  molecules.  The  purified Db/Ddwt  (pDb/ 
Ddwt) and Db/DdLys (pDb/D%ys)  were analyzed using solid- 
phase ELISA (28) (Table 1). Both pDb/Ddwt and pDb/DdLys 
were  strongly  positive  for  the  B22.249  (D  b  od)  epitope; 
while  negative  for  the  34-5-8s  epitope  (D  d clloL2).  As  ex- 
pected, the pDb/Ddwt, but not the pDb/DdLys, was reactive 
with 34-2-12s (D  d o~3) since the D d Glu227-+Lys substitu- 
tion abrogates recognition by 34-2-12s (13,  14). All prepa- 
rations were standardized by protein and ELISA assays. 
The pDb/Dawt, pDb/DdLys, and pD  b (isolated from EL4 
cells) were immobilized separately on microtiter plate wells, 
pulsed  with  NP  peptide  at  the  concentrations  indicated, 
and  tested  for  their  abilities to  trigger H-2  Db-restricted, 
NP-specific CTL  (Fig. 3).  As we have  shown previously 
(7,  32),  the  NP-specific  CTL  clone  3/4  bound,  and  de- 
granulated in  response  to,  the immobilized pDb-Np pep- 
tide complexes (Fig. 3). Clone 3/4 cells also bound to both 
pDb/Ddwt  and pDb/DdLys,  but  the  levels of binding and 
response  are dramatically different  (Fig. 3  A). We  consis- 
tently observed that the maximal percentage of clone 3/4 
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Figure  3.  Comparison  of influenza  NP~specific  CTL  clone adhesion 
and  SE  release  to  immobilized  pDb/Ddwt  and  pDb/DdLys  complexed 
with  NP  peptide.  The  pDb/Ddwt,  pDb/DaLys,  and pD  b were  immobi- 
lized at a density of 0.1  txg/well, and pulsed with NP peptide at the con- 
centrations indicated.  Clone 3/4 CTL were loaded at 2  X  10S/well, and 
incubated  at 37°C for 4  h.  The  CTL adhesion (A) and degranulation  as 
measured by SE release (/3) were determined simultaneously. Nonspecific 
binding (3.4%) was subtracted. Results are expressed as the mean of tripli- 
cate  wells and variation  is <10%  of the mean.  [Z], pDb/Dawt;  O,  pDb/ 
DdLys; ~, pD  b. 
CTL  cells  adhered  to  immobilized  pDb/Ddwt  was  more 
than threefold greater than to pDb/D%ys  (38%  compared 
with  10%).  CTL  binding  to  both  pDb/Dawt  and  pDb/ 
DdLys was peptide dose dependent and reached plateau at 
10  laM  NP peptide, which probably represents a peptide 
concentration resulting in saturation of peptide binding by 
the immobilized class I molecules. CTL SE release response 
showed very similar results  (Fig. 3 B), and was also peptide 
dose dependent with maximal degranulation a minimum of 
three to five times stronger to pDb/Dawt than pDb/D%ys. 
The pDb/Ddwt and pDb/DdLys density dependence for 
CTL binding and degranulation was also investigated  (Fig. 4). 
Both pDb/Ddwt and pDb/DdLys were coated separately at 
several densities and pulsed with a saturating concentration 
of NP peptide. CTL adhesion (Fig. 4 A) and degranulation 
response (Fig.  4  B) was  density dependent for pDb/Ddwt 
and  pDb/DdLys,  with  pDb/Ddwt  supporting  a  threefold 
greater maximal CTL binding (Fig.  4 A)  and triggering a 
fivefold stronger maximal degranulation response (Fig. 4 B) 
than pDb/DdLys. When a saturating amount ofpeptide was 
used to pulse both the pDb/Ddwt and pDb/DdLys at or be- 
low saturating densities (0.025  lag/well or less), 8-16-fold 
more pDb/D%ys molecules were required to reach the same 
level  of CTL binding  to  pDb/Dawt  pulsed  with  peptide 
(Fig.  4 A). About a  10-fold higher density of pDb/DaLys 
was needed to induce a similar level of clone 3/4 SE release 
as needed for pDb/Ddwt, with saturating peptide (Fig. 4 B). 
An ELISA of immobilized pDb/Ddwt and pDb/DaLys done 
in parallel using Db-specific mAb, B22.249, confirmed that 
at the same input of purified class I protein, the immunore- 
active  D b  epitopes  for  both  pDb/Dawt  and  pDb/D%ys 
were at comparable density (Fig. 4 C). Clone 3/4 adhesion 
(Fig.  5, A and B) and SE release (Fig.  5,  C and D) to both 
NP-pulsed  pDb/Ddwt  and  pDb/D%ys  were  significantly 
inhibited by anti-CD8 mAb, 2.43 and YTS169.4, suggest- 
ing  that  not  only the  pDb/Ddwt,  but  also  the  low level 
pDb/D%ys-triggered responses  are  CD8  dependent,  thus 
the pDb/DdLys may still interact to some extent with CD8 
molecules despite the Glu 227-->Lys substitution in the ix3 
domain. 
In summary, these results  indicate that the Glu227--)Lys 
mutation in the cx3 domain of class I raises the threshold of 
class  I  density  required  for  CDS-dependent  Ag-specific 
CTL  binding  and  response  severalfold,  and  substantially 
lowers the  maximal response achieved.  This provides the 
first  direct quantitative comparison of the  ability of wild- 
type and el3 mutant class I molecules to serve as Ag-pre- 
senting molecules, since it excludes the potential participa- 
tion of both defined and undefined non-class  I  accessory 
molecule interactions. 
Both the pDb /Dawt and pD~ /DaLys Serve as Effective Ligands 
for TCR-ttiggered CD8 Adhesion and CTL Response.  CD8 can 
function both as a "coreceptor" and as an "accessory mole- 
cule"  during CTL recognition (5-10,  24).  Evidence sug- 
gests  that  when  TCR  is  triggered,  signals  are  generated 
which activate CD8 to a state of higher avidity, and conse- 
quently, the activated avidity-enhanced CD8 binds MHC 
class I molecules and facilitates  CTL activation (6-10). For 
instance, soluble Ab to TCR alone is not a sufficient stimu- 
lus for CTL degranulation, however it can trigger avidity- 
enhanced CD8  accessory-type binding to non-Ag class I 
and  cosignaling function, resulting in  CTL degranulation 
(6-8). As shown above, the Db/DaLys mutant class I could 
not  effectively activate  CTL.  One  possibility  that  could 
contribute to this result would be that the Db/D%ys mole- 
cule  does  not  serve as  an  effective ligand  for TCR-acti- 
vated CD8  as  compared to  Db/Dawt  molecules.  To  test 
this possibility, we stimulated the Kb-specific CTL clone 11 
with  soluble  anti-TCIk  mAb  (H57.597),  and  determined 
whether the CTL bind to immobilized pDb/Ddwt or pDb/ 
D%ys,  non-Ag  class  I  molecules  in  this  system  (6-8). 
Clone  11  triggered by fluid-phase anti-TC1K-ci/[3 bound 
substantially to both pDb/Ddwt and pDb/DdLys in a den- 
sity-dependent manner (Fig.  6 A), but not to the purified 
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Figure 4.  Density dependence of isolated wild-type and mutated ol3 domain class l for Ag-specific CTL adhesion and SE release response. The pDb/ 
Ddwt (squares)  and pDb/DaLys (circles)  were immobilized on microtiter plate wells at the indicated densities, and pulsed with NP peptide at a saturating 
concentration of 75 btM. NP-specific clone 3/4 CTL cells were loaded into the wells at 2 X 10S/well,  and incubated at 37°C for 4 h. The CTL adhesion 
(A) and degranulation as measured by SE release (B) were done simultaneously from the same wells. Nonspecific binding (4.1%) was subtracted. (C) 
Solid-phase ELISA ofpDb/Ddwt and pDb/DdLys  molecules. The pDb/Ddwt (squares)  and pDB/DdLys  (circles) molecules used in binding (A) and SE release 
(B) assays  were titrated on the plates at the same densities. Their ELISA reactivities  were determined by using a Db-specific  mAb, B22.249, and results are 
expressed as the mean of duplicate wells. 
murine  class II molecule,  I-E  d (data not  shown).  We  also 
compared  the  ability  of  the  pDb/Dawt  and  pDb/DaLys 
molecules  to  provide  CD8-dependent  cosignals for  CTL 
degranulation in conjunction with soluble anti-TCR anti- 
body. Both pDb/Dawt and pDb/DaLys were found to effi- 
ciently activate CTL degranulation response in conjunction 
with a low concentration of soluble anti-TCP, mAb that is 
otherwise insufficient to stimulate degranulation (Fig. 6  B). 
The  soluble  anti-TCP,-o~/[~  triggered  CTL  binding  and 
degranulation  to  pDb/DdLys  is  comparable  to  or  slightly 
lower (70-90%) than that ofpDb/Dawt throughout the im- 
mobilized class  I  MHC  density curves  (Fig.  6,  A  and  B, 
data not shown).  Both binding and SE release of clone  11 
in  response  to  either  pDb/Ddwt  or  pDB/DdLys  non-Ag 
class I molecules was blockable by an anti-CD8 mAb, 2.43 
(Fig.  6,  A  and  /3),  indicating that  the  soluble TCP,.  mAb 
triggered CTL  binding  to  the  immobilized class  I  mole- 
cules and observed SE release is mediated by CD8 in an ac- 
cessory-type interaction. The Kb/Ddwt and Kb/DdLys class 
I molecules were also purified and tested for their ability to 
serve as TCtL-triggered, avidity-enhanced CD8 ligands for 
adhesion  and  response,  and  yielded similar results  to  the 
Db/Ddwt and Db/DdLys (data not shown). 
We have demonstrated previously that a suboptimal CTL 
adhesion  and  response  to  specific Ag class  I  can  be  aug- 
mented  when  non-Ag  class  I  is  coimmobilized  (7,  27). 
Augmentation of adhesion and degranulation by the non-Ag 
class I was shown to be mediated by CD8 in an accessory as 
opposed  to  coreceptor  capacity  (7,  27).  We  examined 
whether  pDB/Ddwt  or  pDb/DaLys  can  serve  as  non-Ag 
CD8  accessory ligands to  enhance  CTL  binding and  de- 
granulation. Both pDb/Dawt and pDB/DdLys were titrated 
and  coimmobilized with  a  suboptimal density of purified 
K b alloantigen on the wells. The binding and SE release of 
the K b allo-specific clone  11  in response to suboptimal K b 
and  coimmobilized pDB/Ddwt  or pDB/DdLys were  deter- 
mined (Fig. 7). Augmentation of clone 11  binding (Fig. 7 A) 
and triggering of degranulation (Fig. 7  B)  facilitated by the 
coimmobilized pDb/Dawt or pDB/DdLys was to very simi- 
lar levels throughout the class I density curves. As expected, 
the enhanced binding and augmented SE release facilitated 
by  both  pDb/Dawt  and  pDb/DaLys  were  mediated  by 
CDt,  as  anti-CD8  mAbs  significantly blocked  clone  11 
binding and response (Fig. 7, A  and B). We also found that 
the coimmobilized pKb/Ddwt or pKb/DdLys molecules are 
equally effective  as  avidity-enhanced CD8  ligands to  en- 
hance CTL binding and degranulation when the Db-restricted, 
NP-specific CTL clone 3/4 is triggered by suboptimal Db-Np 
peptide complexes (data not shown). Taken together, these 
results  show  that  the  Glu227-gLys  substitution  in  the  c~3 
domain of class I molecules does not abrogate the ability of 
class I  to serve as a ligand for activated CD8  accessory in- 
teractions. This indicates that the Glu227  in murine class I 
molecules is not required for TCP,-triggered CD8 binding. 
Since  the  class  I  o~3  domain  mutants  can  still  effectively 
serve as avidity-enhanced CD8  ligands, the poor ability of 
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Figure 5.  CD8 dependency  of 
NP-specific CTL  adhesion and 
degranulation  in  response  to 
pDb/Ddwt  -  and pDb/DdLys-NP 
peptide complexes. Both pDb/ 
Ddwt (A and C) and pDb/DdLys 
(B and D) were immobihzed on 
plastic at  a density of 0.1  Ixg/ 
well, and pulsed with NP pep- 
tide at the concentrations  shown. 
Clone  3/4  CTL  cells were 
loaded into the wells at 2 ×  105 
per well, and incubated at 37°C 
for 4 h. The CTL adhesion (A 
and  B)  and  degranulation  as 
measured by SE release (C and 
D)  were carried out  simulta- 
neously. Anti-CD8 mAb inhibi- 
tion  of both  adhesion and  SE 
release were performed as  de- 
scribed in Materials and Meth- 
ods. Anti-CD8 mAb, 2.43, was 
used at 1:4 dilution of culture su- 
pernatant,  and  YTS169.4  was 
used at  the  concentration of 5 
txg/ml. All results are the mean 
of triplicate,  wells. 
pDb/DdLys to trigger CTL adhesion and degranulation re- 
sponse is not explained by an inability to bind to CD8 per se. 
The  a3  Glu227-+Lys  Substituted H-2  Class I-Peptide 
Complexes Are Defective in Initiating TCR Signals  for Avidity- 
enhanced  CD8  Binding  to  Non-Ag  Class  I  and  CTL  Re- 
sponse.  Since the DU/DdLys  molecules can serve as effective 
non-Ag class I  ligands for TCR.-activated, avidity-enhanced 
CD8  (Figs.  6  and 7),  we investigated whether Db/DdLys  - 
peptide complexes are  defective in initiating TCR. signals 
for avidity-enhanced, CD8-dependent CTL adhesion and 
response.  We  and  others  have  shown  that  a  suboptimal 
density of class  I  or soluble anti-TCR, mAb, which is not 
sufficient to fully activate CTL, can initiate TCR. signaling 
which  in turn  enhances CD8  binding to  non-Ag MHC 
class I and augments CTL adhesion and responses (6,  7, 9, 
10).  To  test  their  effectiveness  in  initiating early  TCR.- 
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dependent events in T  cell activation, both the pDb/Ddwt 
and pDb/DdLys were titrated and coated on plastic with or 
without coimmobilization of a  non-Ag class  I  molecule, 
K k. After pulsing the immobilized class I with NP peptide, 
clone 3/4 CTL were added to the wells and their enhanced 
binding and SE  release  to  coimmobilized non-Ag class  I 
were determined (Fig. 8).  Coimmobilized K k greatly aug- 
mented clone 3/4 adhesion (Fig. 8 A) and SE release (Fig. 
8  B)  in response to pDb/Dawt-NP complexes. This effect 
was observed at the pDb/Ddwt input as low as 0.0008 Ixg/ 
well for enhanced binding (Fig.  8  A),  and 0.006  Ixg/well 
for augmented degranulation (Fig. 8 B), while at these con- 
centrations, pDb/Dawt alone does  not trigger CTL adhe- 
sion or degranulation response. In contrast, over a range up 
to 0.05 Ixg/well input (approaching immobilization satura- 
tion), pDb/DdLys did not trigger CTL for enhanced bind- A 
C 
"O 
t,, 
In 
o 
o 
O  n 
¢,/} 
B 
@ 
I,M 
40.0% 
30.0%. 
20.0% - 
10.0% - 
0.0% "t 
T 
.L 
a. 
0.00  0.05  0.10  0.15 
0.25 
0.20-  T~T 
0.1,_  // 
000b'-_v"  ÷  ;  ;~  ............. ? 
o.oo  o.o5  o.m  o.~5 
Purified  chimeric  class  I  input  (l~g/well) 
Figure  6.  Soluble anti-TCR-c¢/[3 mAb triggers CD8-dependent CTL 
binding and response to  pDb/Dawt  and  the c~3  domain mutant,  pDb/ 
DaLys.  The pDb/Ddwt and pDb/DaLys were separately immobilized on 
the wells at  the indicated densities. The  K  b alloreactive clone 11  CTL 
were resuspended with the anti-TCR-c~/[3 mAb, H57.597,  at a concen- 
tration of 0.5 ~g/ml immediately before loading into wells. For anti-CD8 
mAb blocking, clone 11 cells were incubated at room temperature for 30 
rain with 2.43 mAb (1:4 dilution of culture supematant) before the addi- 
tion ofanti-TCR mAb.  1.5  X  10 s clone 11  cells were loaded into wells 
and incubated at 37°C for 4 h. Clone 11 binding (A) and SE release (B) of 
clone 11  cells were determined. Results were expressed as the mean + 
SD. Clone 11 binding to BSA (3.9%) was treated as background and sub- 
tracted. Clone 1l  without soluble anti-TCR-~x/~ stimulation bound to 
0.15  gtg/well input of both pDb/Ddwt and pDb/DdLys to a similar back- 
ground level as clone 11 binding to BSA (data not shown). U1, pDb/Ddwt; 
II, pDb/Ddwt +  2.43;  O, pDb/DdLys; O, pDb/DdLys q- 2.43. 
ing or SE  release when coimmobilized with K k (Fig.  8, A 
and B). These results indicate that the o~3 domain mutation 
in MHC class I molecules likely affects initial low avidity or 
basal CD8 binding to class I-peptide Ag complexes which 
interferes with its CD8 coreceptor function, but not subse- 
quent avidity-enhanced CD8 binding and accessory function. 
Discussion 
In the present report, we describe the direct comparison 
of wild-type MHC  class I molecules with those bearing a 
Glu227-+Lys  or3  domain  mutation  previously  shown  to 
substantially diminish or abrogate CD8-dependent CTL ly- 
sis  (4,  13,  14,  24),  in mediating As-specific, CD8-depen- 
dent CTL clone adhesion and response. This was explored 
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Figure  7.  The pDb/Ddwt and pD6/DdLys cO domain mutant function 
equally well as CD8 accessory ligands for augmenting CTL binding and 
SE release when coimmobilized with suboptimal specific alloantigen. Pu- 
rified K b isolated from EL4 cells was immobilized on plastic  at a subopti- 
mal density of 0.02 txg/ml alone or together with the pDb/Ddwt or pDb/ 
DdLys at the indicated densities. Clone 11 binding (A) and SE release (B) 
in response to coimmobilized suboptimal K b and pDb/Ddwt (open squares) 
or pDb/D%ys (open circles) at various densities were determined. Binding 
of clone 1 t  to immobilized suboptimal K b alone was 4.9%.  Clone 11  SE 
release  to  suboptimal  K  b  Ag  was  at  the  background  level  (data  not 
shown). Effects of the anti-CD8 mAb, 2.43,  on suboptimal K b As-trig- 
gered  CTL  binding  (A)  and  enhanced  degranulation  response  (B)  to 
coimmobilized pDb/Ddwt (solid squares)  or pDb/DdLys (solid circles) were 
also examined. Results are expressed as mean of triplicate wells and varia- 
tion is <10% of the mean. D, pDb/Ddwt; O, pDb/DaLys; II, pDb/Ddwt + 
2.43; O, pDb/DdLys +  2.43. 
using  purified MHC  molecules  on  solid phase,  where  the 
density of class I  and the number  ofpeptide  antigen-class I 
complexes  were  varied in  a  controlled  manner.  The  num- 
ber  of  peptide-class  I  complexes  formed  on  solid  phase 
with the immobilized  wild-type  and mutant  class I by addi- 
tion  of  exogenous  peptide  antigen  are  likely  to  be  very 
similar,  if not  identical,  since  the  addition  of  exogenous 
peptide  antigen induces peptide-dependent  conformational 
epitopes  to  an  equivalent  extent  on  wild-type  and  e~3  do- 
main  mutated  class  I  molecules  expressed  on  endogenous 
peptide  loading  defective  T2  cells  (24).  Furthermore,  the 
acid-eluted  endogenous  peptides  of K b  and  D b  molecules 
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Figure  8.  The pDb/D%ys-NP peptide complexes are defective  in ini- 
tiating TCR-triggered avidity-enhanced CD8 adhesion to non-Ag class I 
and CTL response. Both the pDb/Ddwt (squares)  and pDb/DaLys (circles) 
were titrated  and immobilized separately  on plastic with (solid symbols)  or 
without (open symbols)  the coimmobilization ofa non-Ag class I molecule, 
K k. Immunoaffinity purified K k was used at a density of 0.20 ~zg/well. Af- 
ter pulsing with 30 I.zM NP peptide,  1.8  ×  105 clone 3/4 CTL cells were 
loaded and incubated at 37°C for 4 h. Clone 3/4 binding (A) and SE re- 
lease (B) were measured simultaneously. Nonspecific binding to BSA was 
5.2%  and  subtracted.  Clone  3/4 binding to  immobilized K  k alone  was 
2.3%.  V1,  pDb/Ddwt alone;  l,  pDb/Dawt +  Kk;  O, pDb/DaLys, alone; 
O, pDb/DdLys +  K k. 
with their respective or3 mutant counterparts appear identi- 
cal,  suggesting  that  the  point  mutation  in  the  ¢x3  domain 
does not affect peptide binding  (24,  34),  despite the obser- 
vation that the Asp227--+Lys substitution  in another class  I, 
L a, diminishes  the interaction  of this  class I  molecule  with 
the  endoplasmic  reticulum  peptide  transporter,  TAP,  dur- 
ing biosynthesis  (35). 
We found the maximal CTL adhesion and degranulation 
response to be at least threefold greater to immobilized pu- 
rified  wild-type  as  opposed  to  mutant  class  F-presenting 
molecules  pulsed  with  peptide.  The  mutant  class  I  mole- 
cules did not achieve >10%  of input  CTL binding,  which 
was only observed at high concentrations  of antigenic pep- 
tide. These results are consistent with the differences in tar- 
get cell lysis and degranulation responses we found with the 
same CTL  clone in  response  to wild-type and mutant  class 
I-bearing target cells. In experiments not easily approached 
using target cells,  we show that in the presence of saturat- 
ing peptide antigen,  it requires an 8-16-fold higher density 
of immobilized  mutant  class  I  molecules  to  achieve  the 
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same level of CTL adhesion and response as with molecules 
bearing a wild-type o~3 domain.  Surprisingly,  we observed 
CTL  avidity-enhanced  CD8  binding  induced  by  soluble 
anti-TCR  mAb or alloantigen not only to class  I bearing a 
wild-type o¢3 domain but also to class I 0~3 mutants which 
lack  a  critical  CD8  binding  site.  Furthermore,  additional 
signaling  associated  with  avidity-enhanced  CD8  binding 
was  only modestly  reduced  or  undiminished  with  the  oL3 
domain  mutant  class  I  relative  to  wild-type  molecules  in 
the two experimental systems used. In contrast, when incu- 
bated  with  peptide  antigen,  the  mutant  class  I  molecules 
were  unable  to  trigger  TCR-dependent  signals  necessary 
for  the  induction  of  avidity-enhanced  CD8  binding  to 
coimmobihzed non-antigen  class I. 
Several amino acid substitutions  in the acidic loop of the 
conserved  cx3  domain  of class  I  disrupt  CD8-dependent 
CTL antigen recognition  (4, 13-15, 33). This is likely to be 
due to interference with CD8  coreceptor function since the 
mutagenesis of the antigen-presenting  class I, the ligand for 
the TCR,  blocks response despite the presence of non-Ag 
class I  on the same cell membrane,  which  in theory could 
serve  as  accessory ligands  for CD8.  More  direct  evidence 
for CD8  serving a  coreceptor adhesive  role has been pro- 
vided recently by Luescher et al.  (10)  who examined CTL 
interactions  with soluble wild-type and or3 mutant K a class 
I  molecules.  Using  photoaffinity  labeling  techniques  they 
directly  demonstrated  that  CD8  can  serve as a  coreceptor 
by significantly strengthening  cell surface TCR  binding to 
soluble K d on an allo-specific CTL clone and this  interac- 
tion was shown to be inhibited by a Lys substitution for the 
Asp227 in K d. However, there was no analysis of functional 
responses possible in this system to determine  the relation- 
ship  of binding to response,  since  class  I in soluble mono- 
meric form is not a stimulus for T  cell responses. Our studies 
with  solid  phase  class  I  provide  a  quantitative  comparison 
of class  I  molecules  bearing  wild-type  or  the  013  domain 
mutation  for  CTL  adhesion  and  response.  Our  data  are 
consistent with and strengthen  the conclusions  of previous 
reports suggesting that the  Glu227  mutation  disrupts  CD8 
coreceptor  interactions,  as  our  results  reveal  that  CD8 
coreceptor engagement  with peptide  antigen-class  I  com- 
plexes  is  necessary  for the  TCR-dependent  expression  of 
avidity-enhanced  CD8 binding to non-Ag class I and CD8 
accessory function by CTL. 
Binding  and  response  to class I-bearing cells or surfaces 
by  CTL  appears  to  be  a  dynamic  multistep  process  con- 
trolled by the  TCR  (8).  For example,  no  detectable  CTL 
binding  is observed to immobilized  non-Ag  class  I  in  the 
absence  of a  TCR  stimulus  (6,  7),  thus  CD8  interaction 
with class I is likely to be minimal in the absence of TCR 
triggering.  However, if the TCR  is engaged with immobi- 
lized specific antigenic  class  I, high  avidity CD8  accessory 
interaction  with coimmobilized non-Ag class  I is observed 
and this  results in the  delivery of additional  signals leading 
to phosphatidylinositol hydrolysis and degranulation  of CTL 
(6, 7, 36).  That this process is likely to be sequential is sup- 
ported by the  observation  that pretreatment  of CTL with 
low concentrations  of soluble antibodies  to the TCR  used to  mimic  antigen  recognition,  triggers  subsequent  high 
avidity CD8 binding to class I  (6, 7). The CD8 avidity en- 
hancement is blocked by inhibitors  of tyrosine phosphory- 
lation suggesting that this process is dependent  on intracel- 
lular signaling (6, 36). Since the oL3 domain mutant class I is 
defective in supporting  appropriate  triggering through  the 
TCR  for  CD8  binding  in  the  presence  of an  excess  of 
coimmobilized non-Ag class I  (Fig. 8), our results suggest a 
sequential model of CD8 receptor functions.  In this model, 
the  Glu227  of H-2  class  I  is essential for early low avidity 
CD8  coreceptor  function  in  stabilizing  TCR  engagement 
with  class  I  and  facilitating  initial  TCR  activation  signals, 
but  not  for  subsequent  avidity-enhanced  CD8  accessory 
molecule recognition  and function which may involve ad- 
ditional  binding sites on class  I  molecules.  We  do  not  ex- 
clude the possibility that when CD8 undergoes avidity en- 
hancement it may also augment  CD8  coreceptor function, 
but the  expression  of activated CD8 binding,  regardless  of 
whether the class  I ligand is presenting the peptide antigen 
or not, would still be dependent on initial low avidity CD8 
interactions. 
It has been  difficult  to  determine  the  relative  contribu- 
tions  of CD8  coreceptor  and  accessory functions  to  CTL 
activation.  However,  since  mutagenesis  of the  ci3  domain 
of the  specific  Ag-presenting  class  I  molecule  (potential 
CD8  coreceptor  ligand)  can  ablate  CD8-dependent  CTL 
reactivity even in the presence of endogenous non-Ag class I 
(potential CD8 accessory ligand), it has been suggested that 
CD8  functions  much more efficiently as a coreceptor than 
an accessory molecule  (15,  24).  Results  in  the  present  re- 
port indicate  that this  simple interpretation  can be signifi- 
cantly revised and  clarified.  Our  data support  the  conclu- 
sion that the induction  and expression of avidity-enhanced 
CD8  accessory function  is simply dependent  on  an  initial 
CD8  coreceptor priming  function  and  CD8  accessory in- 
teractions can be critical for CTL responsiveness at low an- 
tigen  density.  Thus  both  CD8  coreceptor  and  accessory 
functions  are  important  for  CTL  activation.  Without  the 
initiating TCR-dependent  CD8  coreceptor activity which 
is  prevented  or  greatly  diminished  by  the  Glu227--+Lys 
mutation,  however,  no  avidity  enhancement  of CD8  oc- 
curs in response to or3 mutant class I-peptide antigen com- 
plexes  and  no  subsequent  CD8  accessory function  can be 
observed. Therefore,  our results provide an explanation for 
why little or no response is observed when peptide antigen 
is presented  by the  or3  domain  mutant  class  I,  despite  the 
presence  of non-Ag  class  I  that in principle  might be  ex- 
pected  to  compensate  as  CD8  accessory ligands  for  defi- 
ciencies in the o~3 mutated class I presenting molecules. 
Interestingly, we found that the o~3 domain mutant class I 
molecule  is  still  an  effective  ligand  for  avidity-enhanced 
CD8  binding,  however  it  is  unclear  at present  how  CD8 
binds  the  mutant  molecules.  This is hampered by the lack 
of  understanding  regarding  how  the  avidity  of  CD8  is 
modulated by TCR  triggering.  It is clear from cell transfec- 
tion and adhesion assays that the conserved or3 domain res- 
idues  222-229  acidic  loop  that  includes  Glu/Asp227  is  a 
binding site on class I for CD8o~ homodimers when CD8ot 
is  overexpressed  (15).  Independent  confirmation  of an or3 
binding  site  for CD8ot  was provided  by Fayen  et al.  (37) 
who  showed  that the  human  CD8ot  IgV domain  and  the 
or3  domain  of HLA-A2.1  can  interact  in  soluble  and  im- 
mobilized forms and thus these domains of CD8 and class I, 
respectively, are sufficient for binding in vitro. It is possible 
that avidity-enhanced  CD8 binding to mutant class I is still 
to the acidic loop of class I or3 domain, however its binding 
may be less dependent than CD8 in its low avidity state on 
the presence of Glu227.  We have reported previously that 
avidity-enhanced  CD8 binding is diminished by agents that 
inhibit  cytoskeletal  modifications  (38).  A  consequence  of 
cytoskeletal changes in response to TCR  triggering may be 
an increase  in  cell spreading resulting  in  an increased  sur- 
face area of contact. By increasing the area of contact,  CTL 
would  increase  the  quantity  of CD8  that  might  engage 
class  I on a target cell surface or on solid phase and the in- 
creased  number  of interactions  of CD8  with  class  I  be- 
tween  the  two  surfaces may be sufficient  to support  stable 
binding.  A  second  consequence  of cytoskeletal  rearrange- 
ments induced by TCR  triggering may be CD8 microclus- 
tering as found with the C3bi receptor (39), increasing the 
multivalency of CD8 and in turn increasing the avidity but 
not  necessarily  the  affinity of CD8  for class  I.  In both  of 
these  scenarios,  avidity  increases  between  the  CD8  and 
class  I-bearing surfaces may compensate  for reductions  in 
CD8  affinity  from  the  Glu227-->Lys  mutation  without  a 
change in CD8 binding site on class I. 
It  has  recently  been  reported  by  Sun  et  al.  (17)  using 
transfection and overexpression systems that substitutions in 
the cx2 domain of HLA class I can disrupt cell-cell adhesion 
mediated  by  human  CD80~/ot,  suggesting  that  CD8  may 
have  additional  contact  or binding  sites  on  class  I  outside 
the  or3  domain.  Furthermore,  recent  studies  using  exon 
shuffling of domains between human and mouse class I genes, 
have  provided  evidence  to  suggest  that  the  cx2  domain  is 
likely to influence  CD8  interactions  with  class  I  in  T  cell 
development  and  mature  CD8 +  T  cell reactivity  (40,  41). 
Although  additional  CD8  binding  sites  on  class  I  may be 
involved in basal or low avidity CD8 binding,  CD8 inter- 
action  with  these  additional  sites  may be  enhanced  upon 
TCR  triggering and support activated CD8 binding despite 
the Glu227-+Lys mutation. 
The  preceding  discussion  has  not  considered  structural 
changes of CD8 that may result from TCR  triggering.  It is 
conceivable that the CD8 heterodimer undergoes a confor- 
mational change  resulting from TCR-triggered  intracellu- 
lar signals,  which  enhance  CD8  affinity for the  or3  acidic 
loop or alternatively allows CD8 to bind additional sites on 
class  I.  This  may provide  an  explanation  for our  observa- 
tion  of activated  CD8  adhesion  to  the  mutant  molecules. 
In this  context,  Meyerson  et  al.  (42)  have found  that  the 
presence of the membrane proximal connecting peptide or 
stalk  of CD8  reduces  NH2-terminal  CD8ot  IgV  domain 
binding  to  the  cx3  domain  and  the  binding  of purified 
CD8ot  in  soluble  form  to  class  I  is  temperature  sensitive. 
1680  CD8 and MHC Class I Interactions in CTL Activation These results could suggest that a specific or preferred con- 
formation of CD8 or class I may be necessary for binding. 
Perhaps TCR-triggered changes in CTL lead to the induc- 
tion  or  stabilization  of appropriate  CD8  conformation(s) 
for class  I binding.  In contrast to the report of Meyerson 
et  al.  and  others  involving  CD8ot/oL  homodimers,  our 
study examines  class  I  adhesion by CD8ot/[3 heterodimers 
which  are  typically expressed  on mature  murine  CD8 + 
T  cells.  Expression or lack thereof, of the CD8 13 chain has 
been shown to substantially influence T  cell thymic matu- 
ration  (43-45)  and  CD8  13  undergoes  structural  changes 
depending  on  T  cell  differentiation  and  activation  state 
(46).  It is less  clear whether the CD8 13 chain directly par- 
ticipates  in  mature  T  cell  recognition  of class  I  (47-49), 
however it remains to be determined whether the  CD8 13 
chain  may influence  or possibly  regulate  basal  or avidity- 
enhanced CD8 binding to class I. 
We show that the purified Glu227-->Lys oL3 mutant mole- 
cules bound with peptide antigen are very poor ligands for 
CTL  adhesion  and  response,  yet  there  is  still  some  low 
level CTL reactivity to these mutant class  I-antigen com- 
plexes.  It is not clear how the CD8-dependent CTL clone 
is responding to the mutant class I molecules, but responses 
are only found at relatively high concentrations  of peptide 
and  this  is  also  true  for peptide-pulsed  target  cells  (Fig.  1 
and 2; 24).  The CTL responses to the mutant class I com- 
plexes  on cells  and  solid phase  however were  partially  or 
completely inhibited  by CD8-specific  antibodies,  suggest- 
ins that CD8 is still participating in mutant class I molecule 
recognition.  The  combination  of  multiple  low  affinity 
TCR  and  residual  low  avidity  CD8  interactions  may be 
sufficient to support the low level binding and response ob- 
served  with  the  mutant  class  I  presenting  molecules  and 
peptide.  Alternatively  or additionally,  at high mutant class 
I-antigen  complex  density  there  may  be  some  minimal 
TCR-dependent  signaling  resulting  in  a  small  degree  of 
avidity enhancement of CD8 binding, but if this occurs it is 
inefficient, since we only observe a low level of CTL bind- 
ing and response. 
The  induction  of avidity-enhanced  CD8  binding  re- 
quires tyrosine phosphorylation but not downstream signal- 
ing  events  such  as  phosphatidylinositol  hydrolysis  (6,  36). 
The  specific  intracellular  signaling  molecules  associated 
with this phenomenon however have not been character- 
ized.  In contrast to APCs expressing wild-type class I anti- 
gen,  cells expressing or3 domain mutant class  I antigen fail 
to stimulate CTL phosphatidyhnositol hydrolysis (25).  Other 
intracellular changes that may be elicited in CTL upon en- 
gagement with the or3 domain mutant class I-peptide com- 
plexes have not been described. However, since the mutant 
molecule-peptide complexes fail to stimulate  CTL avidity- 
enhanced CD8 binding,  they may provide, by comparison 
with wild-type class I-peptide complexes, a means to iden- 
tify CTL transmembrane  signaling events resulting in avid- 
ity-enhanced CD8 binding. 
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